Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
about
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisInsights into Newer Antimicrobial Agents Against Gram-negative BacteriaStructure-based optimization of the terminal tripeptide in glycopeptide dendrimer inhibitors of Pseudomonas aeruginosa biofilms targeting LecAMultivalency effects on Pseudomonas aeruginosa biofilm inhibition and dispersal by glycopeptide dendrimers targeting lectin LecAComparative Transcriptome Analysis Reveals Cool Virulence Factors of Ralstonia solanacearum Race 3 Biovar 2Cinnamide Derivatives of d-Mannose as Inhibitors of the Bacterial Virulence Factor LecB from Pseudomonas aeruginosaAn array-based method to identify multivalent inhibitors.Rational design and synthesis of optimized glycoclusters for multivalent lectin-carbohydrate interactions: influence of the linker arm.Specific association of lectin LecB with the surface of Pseudomonas aeruginosa: role of outer membrane protein OprF.Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors.Multivalent glycoconjugates as anti-pathogenic agentsBlood Groups in Infection and Host Susceptibility.Host-microbiome interactions in acute and chronic respiratory infections.Preventing Pseudomonas aeruginosa and Chromobacterium violaceum infections by anti-adhesion-active components of edible seeds.Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumoniaNovel therapeutic strategies to counter Pseudomonas aeruginosa infections.Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis.Biomolecular Mechanisms of Pseudomonas aeruginosa and Escherichia coli Biofilm Formation.Toward the Rational Design of Galactosylated Glycoclusters That Target Pseudomonas aeruginosa Lectin A (LecA): Influence of Linker Arms That Lead to Low-Nanomolar Multivalent Ligands.Pseudomonas Aeruginosa Lectins As Targets for Novel Antibacterials.Pseudomonas aeruginosa lectin LecB inhibits tissue repair processes by triggering β-catenin degradation.Considerations and caveats in anti-virulence drug development.Real-time PCR method for the quantification of Burkholderia cepacia complex attached to lung epithelial cells and inhibition of that attachment.Leaf Extracts of Selected Gardening Trees Can Attenuate Quorum Sensing and Pathogenicity of Pseudomonas aeruginosa PAO1.Development and optimization of a competitive binding assay for the galactophilic low affinity lectin LecA from Pseudomonas aeruginosa.Fluorescent cellular assay for screening agents inhibiting Pseudomonas aeruginosa adherence.Glycosylation is required for outer membrane localization of the lectin LecB in Pseudomonas aeruginosa.Achieving high affinity towards a bacterial lectin through multivalent topological isomers of calix[4]arene glycoconjugates.Overcoming antibiotic resistance in Pseudomonas aeruginosa biofilms using glycopeptide dendrimers.Synthesis of Mannosylated Glycodendrimers and Evaluation against BC2L-A Lectin from Burkholderia Cenocepacia
P2860
Q24202222-3E37AE37-846A-471F-90F5-1E3ED11E81FDQ24234613-AC01A0FE-5E9F-4930-A2F0-736BD9CAE556Q26751255-E1F88445-AB86-4229-8B06-D67B54AE5D90Q27687825-1939BEB3-8CF1-4DF0-91A2-8F255A9DFD5CQ27702214-7CBFBD98-3F04-4458-9578-FFF1668DE440Q28606680-E01417E7-93A6-449E-99B0-60256FF44137Q28830444-9BC9FDFA-4ED2-4F6B-BCA6-821A310E5F01Q34073845-A1A259E7-9283-49BC-9808-F48CC4353C7DQ34226384-0ACA89E3-B58A-48CA-A3A7-C58095D0B2B1Q34442310-8924235F-DF5A-4C53-8D02-26440F4C2594Q34570412-03379513-2CE4-4898-A9DC-20815DFAF5F1Q35444698-0B41DEC9-1374-4E04-B8BB-A4047D65989DQ35763408-42724B9D-061B-4441-90B6-988E2B046517Q35955467-1E640C5D-B81A-44A7-9B5C-32C588B4496FQ35991817-6DC079B2-E9CF-4933-95D0-C9670814ED28Q36288672-A4256D4A-AC41-41A6-BF74-78FAF160B50EQ37147088-F74EFE87-E01C-463E-A707-AA61E31FAFEBQ37984505-FE3E67CB-2578-426D-B052-8050EF220859Q38153821-B4AE7357-42EF-4C6F-BEC3-9A64EC5C3789Q38273317-087BFCEB-B0E9-4538-851F-A9333685E1F7Q38291727-B8F408FB-7D0D-4418-8011-11249B8A0076Q38530800-F86A9257-1515-4724-A7DB-FB5AD2B59CCFQ38795279-F229CA11-BF15-4B7F-A1AD-6022DEA5EFF1Q38810589-68699EDB-9276-4874-A570-B8DE868EA161Q39722850-372DC24F-1B61-4FC3-9F68-5CC4E704EEA6Q40047796-1E3AF6FE-B90B-4D5B-B335-73D6C9C1757DQ40589364-8EE2B2EB-015F-439D-9FB5-98F5D2FE10C8Q41558989-E8B30C65-76D4-42E0-95E7-5F1541B4967FQ42091271-F4580990-93F7-4B40-AD0E-73ED2D64EC9EQ43254260-67A33304-AAFF-4183-A030-98A76BB80475Q55332362-55B2CBFA-7FDA-403C-B45E-EBEA176FE9F0Q58381333-8793A96E-B9CC-4504-BD54-EAC251941A4B
P2860
Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Inhalation with fucose and gal ...... a in cystic fibrosis patients.
@en
type
label
Inhalation with fucose and gal ...... a in cystic fibrosis patients.
@en
prefLabel
Inhalation with fucose and gal ...... a in cystic fibrosis patients.
@en
P2093
P2860
P356
P1476
Inhalation with fucose and gal ...... a in cystic fibrosis patients.
@en
P2093
Almuth Pforte
Dietrich Mack
Hans-Peter Hauber
Maria Schulz
Peter Zabel
Udo Schumacher
P2860
P304
P356
10.7150/IJMS.5.371
P407
P577
2008-11-17T00:00:00Z